glp 1 generics Industry Hungry For More After Showing Larger GLP-1 Appetite In 2024 When Will GLP-1 Generics Hit

Key Points Available medical therapies for acromegaly are limited by moderate and variable efficacy, the need for life-long monthly intramuscular and/or deep subcutaneous depot, or thrice-daily subcutaneous injections, as well as adverse effects DG3173, an injectable somatostatin receptor ligand (SRL) in development, selectively suppresses secretion of growth hormone and seems to have negligible inhibitory effects on insulin secretion, which suggests it has a favourable hyperglycaemic adverse effect profile The investigational agent CAM2029 slowly releases octreotide from a liquid crystal matrix and is administered subcutaneously via thin, prefilled syringes, which facilitates ease of use and delivery Oral octreotide capsules (which are not yet approved) maintain biochemical control and improve symptoms in most patients who respond to injectable SRL therapy

10.1182/blood-2020-137266 170 ScaliseM.PappacodaG.MazzaT.ConsoleL.PochiniL.IndiveriC

The effects of switching from dipeptidyl peptidase-4 inhibitors to glucagon-like peptide-1 receptor agonists on bone mineral density in diabetic patients

Previously, 13-HODE has been shown to modulate cell death through signaling via peroxisome proliferator-activated receptor (PPAR) 40